|1.||Hypertension (High Blood Pressure)
09/30/1987 - "Penbutolol has proved particularly effective and suitable for the treatment, even on a long-term basis, of recently developed hypertension, especially in its hyperkinetic forms. "
11/01/1996 - "Betapressin is recommended for monotherapy of patients suffering from stages I-II hypertension with eu- and hypokinetic types of hemodynamics."
11/01/1996 - "[The pharmacological effect of betapressin in hypertension]."
06/01/1990 - "Thirty patients suffering from WHO I-II class slight-moderate essential arterial hypertension were treated with a beta-blocker (Penbutolol) alone and once a day to assess its antihypertensive effectiveness and its affect on heart frequency, lipid metabolism and kidney function. "
06/01/1990 - "[Validity of the use of penbutolol in essential arterial hypertension]."
01/01/1993 - "Ventricular arrhythmias during exercise testing and daily activities in patients with stable angina pectoris before and during Aldisem and penbutolol treatment."
04/05/1986 - "[Long-term treatment of stable angina pectoris with penbutolol]."
11/01/1983 - "Haemodynamic dose-response effects of i.v. penbutolol in angina pectoris."
07/01/1981 - "Penbutolol: a preliminary review of its pharmacological properties and therapeutic efficacy in hypertension and angina pectoris."
01/01/1984 - "In order to test the additional efficacy of the combination of a beta blocker (penbutolol 40 mg single dose) with molsidomine (2 mg single dose), a double blind cross-over trial was performed in 30 patients with stable angina pectoris. "
|3.||Renal Insufficiency (Renal Failure)
08/28/1985 - "Penbutolol appears to be an effective beta-blocker and one that could be used appropriately in patients with renal insufficiency."
08/28/1985 - "In this study eight hypertensive patients with renal insufficiency were studied during a three-week placebo period and then for four weeks while taking penbutolol in a dose of 40 or 80 mg daily. "
08/28/1985 - "Effect of oral penbutolol on renal haemodynamics of hypertensive patients with renal insufficiency."
01/01/1985 - "Pharmacokinetics of penbutolol and its metabolites in renal insufficiency."
01/01/1993 - "Unchanged protein binding of penbutolol in renal insufficiency: a possible role of carbamylation."
01/01/1981 - "Penbutolol, which possesses intrinsic sympathomimetic activity, may be useful in the treatment of patients in whom some other beta-blocker has failed to bring about adequate control of the blood pressure, despite marked bradycardia."
06/01/1989 - "The lack of significant bradycardia and the low incidence of other troublesome adverse effects are potential advantages during antihypertensive therapy with penbutolol. "
09/30/1987 - "In addition penbutolol does not cause any significant alterations in the biohumoral parameters of the patients treated and is ideal for combination with dihydralazine, reserpine and dihydrochlorotiazide in the treatment of more stubborn cases, making it possible to reduce the doses of the other drugs without causing bradycardia."
01/01/1981 - "Bradycardia occurred more frequently with atenolol than with penbutolol. "
07/01/1983 - "During the 6 weeks of treatment there was no change in body weight and serious side-effects were not observed, but bradycardia occurred more frequently with atenolol than with penbutolol. "
04/01/1996 - "After receiving a 40 mg single oral dose of penbutolol, the absorption rate constant, apparent volume of distribution and serum clearance of penbutolol were found to be reduced in the cancer group. "
04/01/1996 - "The pharmacokinetic and pharmacodynamic profiles of penbutolol were examined in healthy volunteers and in cancer patients using a pharmacokinetic/pharmacodynamic (pk/pd) model. "
04/01/1996 - "These results show that in cancer patients, a change in the pharmacokinetics of penbutolol occurs (associated with changes in drug protein binding), together with an alteration in the pharmacodynamics."
04/01/1996 - "Penbutolol unbound fraction in serum was statistically decreased (p < 0.005) in the cancer group, according to the increase in the serum levels of alpha 1-acid glycoprotein seen in that group (p < 0.05). "
04/01/1996 - "Pharmacokinetics and pharmacodynamics of penbutolol in healthy and cancer subjects: role of altered protein binding."
|5.||Molsidomine (SIN 10)
|9.||Adrenergic Antagonists (Antiadrenergic Agents)